Studies investigating type 2 inflammation, relevant to conditions like asthma, have demonstrated that type 2 innate lymphoid cells (ILC2s), primarily through the action of interleukin‐13 (IL‐13), can directly induce bronchial barrier disruption by downregulating crucial TJ proteins, such as Occludin and ZO‐1 [13]. This evidence concerns the gene IL13 and asthma.